Observational study of tumor samples for transgene levels after a gene-modified cell therapy and a second cancer

You may qualify if

• Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
• Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.

You can't join if

• Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.
• Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.